TYSABRI® Global Observational Program in Safety (TYGRIS)

This study is ongoing, but not recruiting participants.
Elan Pharmaceuticals
Information provided by:
Biogen Idec
ClinicalTrials.gov Identifier:
First received: May 21, 2007
Last updated: August 2, 2012
Last verified: August 2012

The purpose of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events in patients with multiple sclerosis (MS) treated with TYSABRI® (natalizumab).

Multiple Sclerosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: TYGRIS: TYSABRI® Global Observational Program in Safety

Resource links provided by NLM:

Further study details as provided by Biogen Idec:

Primary Outcome Measures:
  • To determine the incidence and pattern of serious infections, malignancies, and other serious adverse events (SAEs) in patients with Multiple Sclerosis (MS) treated with Tysabri. [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   Samples With DNA

whole blood, serum

Enrollment: 3000
Study Start Date: January 2007
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Detailed Description:

The TYSABRI® Global Observational Program in Safety (TYGRIS) is a safety observational cohort program designed to obtain long-term safety data in multiple sclerosis (MS) patients treated with TYSABRI® in a clinical practice setting in the United States or Canada.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

MS patients treated with TYSABRI in North America


Inclusion Criteria:

  • MS patients in the US and Canada receiving TYSABRI® under standard clinical care for less than or equal to 3 infusions are eligible to participate in TYGRIS.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00477113

United States, Missouri
There may be mulitple sites in this clinical trial. Contact United BioSource Corporation
Kansas City, Missouri, United States, 64111
Sponsors and Collaborators
Biogen Idec
Elan Pharmaceuticals
  More Information

Additional Information:
No publications provided

Responsible Party: Biogen Idec MD, Biogen Idec, Inc.
ClinicalTrials.gov Identifier: NCT00477113     History of Changes
Other Study ID Numbers: 101-MS-402
Study First Received: May 21, 2007
Last Updated: August 2, 2012
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by Biogen Idec:
Multiple Sclerosis

Additional relevant MeSH terms:
Multiple Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on April 17, 2014